Gene test could help breast cancer patients avoid chemotherapy

A study led by University College London suggests the Prosigna test can identify early-stage patients who can safely skip chemotherapy.

A major international study led by University College London (UCL) suggests a gene-expression test called Prosigna can identify certain early-stage breast cancer patients who can avoid chemotherapy without losing long-term safety or outcomes.

The OPTIMA trial tracked more than 4,400 women across the UK, Scandinavia, Australia, New Zealand, and Thailand. About 68% of women who took the Prosigna test were categorized as low risk for cancer returning, and these patients were put on hormone therapy instead of chemotherapy. Five years later, 93.6% of those women were alive and cancer-free, compared to 94.8% for patients with similar tumors who received both hormone therapy and chemotherapy.

The Prosigna test, created by the US company Veracyte, analyzes 50 genes in a breast tumor sample to determine how aggressive a tumor is and how likely it is to spread. It is currently licensed for use in post-menopausal breast cancer that has spread to no more than three lymph nodes. The test is intended for patients with early-stage, hormone-sensitive (ER-positive), HER2-negative breast cancer.

The NHS could reportedly save £4m a year by offering the test to women with low-risk breast cancer. Experts at UCL suggest offering the test to women as young as 40 could save the NHS £654 per patient.

Key facts

  • The Prosigna gene test can help approximately two-thirds of certain breast cancer patients safely avoid chemotherapy.
  • In the OPTIMA trial, 93.6% of low-risk women who skipped chemotherapy were alive and cancer-free after five years.
  • The NHS could save £4m annually by using the test to prevent overtreatment.

Three perspectives

Neutral

The Prosigna test provides a risk of recurrence score to help doctors weigh treatment options alongside factors like tumor size and age.

Positive

The research offers the hope of more tailored cancer care and spares thousands of patients from unnecessary treatment.

Negative

Chemotherapy can cause debilitating and sometimes life-threatening side effects for many women.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

Study identifies racial differences in pancreatic cancer tumor cells
Next storyStudy identifies racial differences in pancreatic cancer tumor cells

All sections

Edition